TRIA-662

DRUG3 trials

Sponsors

Cortria Corporation

Conditions

HealthyHypertriglyceridemiaMixed Hyperlipidemia

Phase 1

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

CompletedNCT01809301

Cortria CorporationHealthy

Start: 2013-03-31End: 2013-05-31Updated: 2013-08-22

The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers

CompletedNCT01930240

Cortria CorporationHealthy

Start: 2007-11-30End: 2008-01-31Updated: 2016-07-26

Phase 2

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

CompletedNCT02008084

Cortria CorporationHypertriglyceridemia, Mixed Hyperlipidemia

Start: 2013-12-31End: 2015-10-31Updated: 2016-01-27